Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6189389 | Brachytherapy | 2014 | 9 Pages |
Abstract
Dose-escalated IGRT and HDR-B both yield excellent clinical outcomes for patients with intermediate-risk prostate cancer. Improved biochemical control with HDR-B for patients with worse pretreatment characteristics suggests that a subgroup of intermediate-risk prostate cancer patients may benefit from dual-modality treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Ovidiu Marina, Gary S. Gustafson, Larry L. Kestin, Donald S. Brabbins, Peter Y. Chen, Hong Ye, Alvaro A. Martinez, Michel I. Ghilezan, Michelle Wallace, Daniel J. Krauss,